Oxycodone/naloxone
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
... OXN, oxycodone/naloxone; TAP, tapentadol; OR, odds ratio; 95% CI, 95% confidence interval; TEAE, treatment-emergent adverse event; CNS, central nervous system; W12; LBPIX, low back pain intensity index; ...
20
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
... under oxycodone/ naloxone (65.2% vs 49.6% for oxycodone and ...under oxycodone/naloxone ...under oxycodone/ naloxone than under oxycodone and morphine ...all ...
13
Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
... Figure 4 Proportions of patients with severe (Numeric Rating Scale [NRS] 7–10), moderate (NRS 4–6), mild (NRS 1–3), or no pain (NRS 0) at baseline and throughout the observation on prolonged-release ...
11
Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination
... (PR) oxycodone with PR naloxone (Targin, Targiniq, Targinact) is approved in many European countries for the treatment of severe to very severe RLS, after failure of dopaminergic ...of ...
5
Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
... of oxycodone (OX- CR), an opioid analgesic, is available in many ...combines oxycodone with naloxone. The oxycodone/naloxone controlled-release formulation (OXN-CR) was designed to ...
9
Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study
... used oxycodone/naloxone as a comparator. Oxycodone is a traditional and “popular” opiod, whose use in the field of muscolo-skeletal diseases is well established and reported in many trials so far ...
7
Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report<div> </div>
... report, oxycodone/naloxone has proved to be an effective and safe drug, providing pain relief as well as increased compliance when redressing wounds and faster healing compared to that in similar ...
5
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
... (PR) oxycodone/naloxone (OXN) tablets contain the opioid agonist oxycodone and the opioid antagonist ...of oxycodone in the gut without compromising its analgesic ...
11
Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports
... Against this background, we report the experience of a tertiary referral center concerning the pain management of two patients with SSc affected by DUs with oral prolonged- release (PR) oxycodone/naloxone ...
5
Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
... Patients and methods: This was a single-center, retrospective, observational study in opioid-naive patients aged $75 years, with moderate to severe chronic pain (.6-month duration) and constipa- tion, who initiated ...
9
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
... infiltration. 2 Opioids are recommended for the manage- ment of moderate/severe cancer pain by the WHO and current guidelines, 1–4 and are recognized as the treat- ment of choice. 2 The semi-synthetic opioid analgesic ...
11
Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
... PR oxycodone/PR naloxone can be an effective strategy in combating pain whilst simultane- ously reducing, or even preventing, constipation and bowel dysfunction, increasing tolerability, and improving QoL ...
13
Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
... Different from the aforementioned studies, our study is the first prospective clinical trial to evaluate the efficacy and safety of OXN-PR and pregabalin in cancer patients with neu- ropathic pain. The target population ...
10
A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
... of oxycodone-PR and OXN-PR in cancer pain, by involving an extremely selected cohort of patients with controlled pain and opioid-induced constipation at ...
11
Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
... of oxycodone with the opioid antagonist naloxone improves not only constipation but also other opioid-related gastrointestinal effects, as suggested by other ...
11
Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
... ADRs typically associated with opioid therapy were generally infrequent but were significantly more frequent with OXY that with OXN; in particular, nausea and vomiting were two to five times more common with OXY than ...
10
Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
... Background: Two-thirds of older people suffer from chronic pain and finding valid treatment options is essential. In this 1-yearlong investigation, we evaluated the efficacy and safety of prolonged-release ...
9
Tapentadol extended release for the management of chronic neck pain
... Tapentadol extended release (ER) is as effective as controlled-release oxycodone 29 and more effective than the oxycodone–naloxone combination in patients with mixed back pain presen[r] ...
11
Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
... the oxycodone–naloxone PR group compared to 43% of the placebo group, while 57% of patients reported at least one adverse event related to treatment during the extension ...the ...
9
Repeated Naloxone Administration for Morphine Overdose in a 1-Month-Old Infant
... Administration of naloxone hydrochloride doses as high as 0.24 mg/kg of body weight to narcotic-free adults produced no demonstrable effects.2 Naloxone hydrochloride in a single dose of [r] ...
5